Chronic hepatitis C in African Americans

Nikolaos Pyrsopoulos, Lennox J Jeffers

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The prevalence of HCV infection is higher in the AA population in comparison with Caucasians and Hispanics. The majority of AAs are infected with genotype 1 and have a high viral load. There is a decreased ability to clear the virus after an acute attack, and the frequency on chronic infection is increased. The rate of progression to cirrhosis is lower in AAs, but once they become cirrhotic, their chance of developing HCC is higher. The AA population has been under-represented in clinical trials, and the initial observation pointing toward a lower SVR arising even from small studies has been confirmed, including studies using the current therapy of PEGIFN plus ribavirin. The use of WBD regimens of ribavirin is promising in the treatment of chronic hepatitis C in AAs.

Original languageEnglish
Pages (from-to)427-438
Number of pages12
JournalClinics in Liver Disease
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2005

Fingerprint

Ribavirin
Chronic Hepatitis C
African Americans
Infection
Viral Load
Hispanic Americans
Population
Fibrosis
Genotype
Observation
Clinical Trials
Viruses
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Chronic hepatitis C in African Americans. / Pyrsopoulos, Nikolaos; Jeffers, Lennox J.

In: Clinics in Liver Disease, Vol. 9, No. 3, 01.08.2005, p. 427-438.

Research output: Contribution to journalArticle

Pyrsopoulos, Nikolaos ; Jeffers, Lennox J. / Chronic hepatitis C in African Americans. In: Clinics in Liver Disease. 2005 ; Vol. 9, No. 3. pp. 427-438.
@article{f190ac4211d949358220cc33bfebc45a,
title = "Chronic hepatitis C in African Americans",
abstract = "The prevalence of HCV infection is higher in the AA population in comparison with Caucasians and Hispanics. The majority of AAs are infected with genotype 1 and have a high viral load. There is a decreased ability to clear the virus after an acute attack, and the frequency on chronic infection is increased. The rate of progression to cirrhosis is lower in AAs, but once they become cirrhotic, their chance of developing HCC is higher. The AA population has been under-represented in clinical trials, and the initial observation pointing toward a lower SVR arising even from small studies has been confirmed, including studies using the current therapy of PEGIFN plus ribavirin. The use of WBD regimens of ribavirin is promising in the treatment of chronic hepatitis C in AAs.",
author = "Nikolaos Pyrsopoulos and Jeffers, {Lennox J}",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.cld.2005.05.005",
language = "English",
volume = "9",
pages = "427--438",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Chronic hepatitis C in African Americans

AU - Pyrsopoulos, Nikolaos

AU - Jeffers, Lennox J

PY - 2005/8/1

Y1 - 2005/8/1

N2 - The prevalence of HCV infection is higher in the AA population in comparison with Caucasians and Hispanics. The majority of AAs are infected with genotype 1 and have a high viral load. There is a decreased ability to clear the virus after an acute attack, and the frequency on chronic infection is increased. The rate of progression to cirrhosis is lower in AAs, but once they become cirrhotic, their chance of developing HCC is higher. The AA population has been under-represented in clinical trials, and the initial observation pointing toward a lower SVR arising even from small studies has been confirmed, including studies using the current therapy of PEGIFN plus ribavirin. The use of WBD regimens of ribavirin is promising in the treatment of chronic hepatitis C in AAs.

AB - The prevalence of HCV infection is higher in the AA population in comparison with Caucasians and Hispanics. The majority of AAs are infected with genotype 1 and have a high viral load. There is a decreased ability to clear the virus after an acute attack, and the frequency on chronic infection is increased. The rate of progression to cirrhosis is lower in AAs, but once they become cirrhotic, their chance of developing HCC is higher. The AA population has been under-represented in clinical trials, and the initial observation pointing toward a lower SVR arising even from small studies has been confirmed, including studies using the current therapy of PEGIFN plus ribavirin. The use of WBD regimens of ribavirin is promising in the treatment of chronic hepatitis C in AAs.

UR - http://www.scopus.com/inward/record.url?scp=22044445411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044445411&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2005.05.005

DO - 10.1016/j.cld.2005.05.005

M3 - Article

C2 - 16023975

AN - SCOPUS:22044445411

VL - 9

SP - 427

EP - 438

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -